Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Nov 29, 2018 1:11pm
107 Views
Post# 29040467

RE:RE:RE:Number needed to treat for RVX-208, the NNT ?

RE:RE:RE:Number needed to treat for RVX-208, the NNT ?"Any idea on an expected NTT?"

NNT is the inverse of the absolute risk reduction (ARR). ARR is the difference in actual event rates between the placebo and test group. T
he NNT should also state the duration and the adverse outcome being prevented. If we assume that apabetalone will elicit a 30% RRR and one guesstimates on the placebo event rate, we can get a ballpark ARR and NNT. For example, if placebo and apabetalone groups showed 12% and 8.4% event rates for 3-point MACE, respectively, at 18 months, this would be a 30% relative risk reduction (RRR) and a 3.6% ARR. 3.6% = 0.036. NNT = 1/ARR = 1/0.036 = 27.7. In other words ~28 patients would have to be treated for 18 months to prevent one 3-point MACE occurrence. If the 30% RRR is held constant, then the ARR will decrease and the NNT will increase as the actual placebo event rate drops. For example, if placebo and apabetalone groups showed 10% and 7% event rates for 3-point MACE, respectively, at 18 months, then the ARR is 3% and the NNT is 1/0.03 = 33.3. 

BDAZ
Bullboard Posts